....................................................... 8 1.2.1 Cancer Vaccines................................................ .......................................................... 8 1.2.2 Identification of Cancer-Specific Immunogenic Epitopes Derived from Somatic Mutations ...................................................... .......................................................................... 9 1.2.3 Preclinical Studies for the Gen eration of a Dendr itic Cell Vacc ine ........................... 9 1.2.4 Rationale for Selecting Define d, Tumor Suppressor and Driver Ne oantigens to use in this Trial............................................................................................................................ 11 1.2.5 Relevant Preclinical and Clinical Experience to Support the Proposed Route and Dose of the DC Vaccine ......................................... ..............................................................